Vergoeding 2018-2022 voor ATC-subgroep A10B : Bloedglucoseverlagende middelen excl. insulines
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| A10BA Biguaniden | 8.700.100 | 9.134.200 | 10.345.300 | 12.048.000 | 12.289.100 |
| A10BB Sulfonylureumderivaten | 7.491.900 | 8.661.500 | 8.908.100 | 10.602.100 | 10.925.300 |
| A10BD Combinaties van bloedglucoseverlagende middelen | 3.648.000 | 3.622.200 | 3.630.200 | 3.518.700 | 3.533.400 |
| A10BF Alfa-glucosidaseremmers | 138.420 | 125.090 | 109.740 | 95.128 | 80.713 |
| A10BG Thiazolidinedionen | 112.350 | 81.449 | 60.943 | 83.232 | 297.530 |
| A10BH Dipeptidylpeptidase-4-remmers | 12.410.000 | 14.413.100 | 15.605.600 | 15.208.700 | 15.432.400 |
| A10BJ Glucagonachtig peptide-1-agonisten (glp-1-agonisten) | 17.773.200 | 26.529.600 | 40.026.600 | 50.379.200 | 80.319.800 |
| A10BK Natriumglucose-cotransporter-2-remmers (sglt-2-remmers) | 5.536.000 | 6.186.500 | 7.379.600 | 10.195.300 | 34.236.200 |
| A10BX Overige bloedglucoseverlagende middelen excl. insulines | 42.598 | 50.757 | 55.573 | 51.168 | 49.558 |
| Totaal | 55.852.568 | 68.804.396 | 86.121.656 | 102.181.528 | 157.164.001 |